Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Indaptus Therapeutics, Inc. stock logo
INDP
Indaptus Therapeutics
$10.22
-5.3%
$10.85
$7.56
$66.64
$6.35M1.3562,520 shs6,806 shs
ObsEva SA stock logo
OBSV
ObsEva
$0.00
$0.08
$2.14
$7.94M0.688.94 million shs300 shs
Cortex Pharmaceuticals Inc. stock logo
RSPI
Cortex Pharmaceuticals
$0.00
-11.1%
$0.00
$0.00
$0.00
$760K0.14446,295 shs5,000 shs
Traws Pharma, Inc. stock logo
TRAW
Traws Pharma
$1.43
-2.1%
$1.47
$0.97
$19.44
$8.07M1.46450,641 shs57,254 shs
Investing Strategies To Help Grow Your Retirement Income Cover

Need to stretch out your 401K or Roth IRA plan? Use these time-tested investing strategies to grow the monthly retirement income that your stock portfolio generates.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Indaptus Therapeutics, Inc. stock logo
INDP
Indaptus Therapeutics
0.00%-12.20%+5.22%-20.96%-82.54%
ObsEva SA stock logo
OBSV
ObsEva
0.00%0.00%0.00%0.00%0.00%
Cortex Pharmaceuticals Inc. stock logo
RSPI
Cortex Pharmaceuticals
0.00%+33.33%-55.56%-65.22%-66.67%
Traws Pharma, Inc. stock logo
TRAW
Traws Pharma
0.00%0.00%-3.38%-27.04%+142,999,900.00%
CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
Indaptus Therapeutics, Inc. stock logo
INDP
Indaptus Therapeutics
2.9223 of 5 stars
3.54.00.00.00.61.71.3
ObsEva SA stock logo
OBSV
ObsEva
N/AN/AN/AN/AN/AN/AN/AN/A
Cortex Pharmaceuticals Inc. stock logo
RSPI
Cortex Pharmaceuticals
N/AN/AN/AN/AN/AN/AN/AN/A
Traws Pharma, Inc. stock logo
TRAW
Traws Pharma
0.1917 of 5 stars
0.02.00.00.01.90.80.0
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Indaptus Therapeutics, Inc. stock logo
INDP
Indaptus Therapeutics
3.00
Buy$238.002,228.77% Upside
ObsEva SA stock logo
OBSV
ObsEva
0.00
N/AN/AN/A
Cortex Pharmaceuticals Inc. stock logo
RSPI
Cortex Pharmaceuticals
0.00
N/AN/AN/A
Traws Pharma, Inc. stock logo
TRAW
Traws Pharma
0.00
N/AN/AN/A

Current Analyst Ratings Breakdown

CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Indaptus Therapeutics, Inc. stock logo
INDP
Indaptus Therapeutics
N/AN/AN/AN/A$10.84 per shareN/A
ObsEva SA stock logo
OBSV
ObsEva
N/AN/AN/AN/A$0.41 per shareN/A
Cortex Pharmaceuticals Inc. stock logo
RSPI
Cortex Pharmaceuticals
N/AN/AN/AN/AN/AN/A
Traws Pharma, Inc. stock logo
TRAW
Traws Pharma
$227K35.05N/AN/A($8.66) per share-0.17
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Indaptus Therapeutics, Inc. stock logo
INDP
Indaptus Therapeutics
-$15.02M-$41.74N/AN/AN/AN/A-333.02%-216.36%8/11/2025 (Estimated)
ObsEva SA stock logo
OBSV
ObsEva
-$58.38M-$0.92N/AN/AN/AN/A-416.36%-92.01%N/A
Cortex Pharmaceuticals Inc. stock logo
RSPI
Cortex Pharmaceuticals
-$2.10MN/A0.00N/AN/AN/AN/AN/A
Traws Pharma, Inc. stock logo
TRAW
Traws Pharma
-$166.52M-$32.81N/AN/AN/A-15,245.81%N/A-193.21%8/21/2025 (Estimated)

Latest RSPI, INDP, OBSV, and TRAW Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
5/15/2025Q1 2025
Traws Pharma, Inc. stock logo
TRAW
Traws Pharma
-$8.04$2.09+$10.13$2.09$0.06 million$0.06 million
5/14/2025Q1 2025
Indaptus Therapeutics, Inc. stock logo
INDP
Indaptus Therapeutics
-$11.48-$8.96+$2.52-$0.32N/AN/A
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
Indaptus Therapeutics, Inc. stock logo
INDP
Indaptus Therapeutics
N/AN/AN/AN/AN/A
ObsEva SA stock logo
OBSV
ObsEva
N/AN/AN/AN/AN/A
Cortex Pharmaceuticals Inc. stock logo
RSPI
Cortex Pharmaceuticals
N/AN/AN/AN/AN/A
Traws Pharma, Inc. stock logo
TRAW
Traws Pharma
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Indaptus Therapeutics, Inc. stock logo
INDP
Indaptus Therapeutics
N/A
1.90
1.90
ObsEva SA stock logo
OBSV
ObsEva
N/A
0.61
0.61
Cortex Pharmaceuticals Inc. stock logo
RSPI
Cortex Pharmaceuticals
N/AN/AN/A
Traws Pharma, Inc. stock logo
TRAW
Traws Pharma
N/A
1.81
1.81

Institutional Ownership

CompanyInstitutional Ownership
Indaptus Therapeutics, Inc. stock logo
INDP
Indaptus Therapeutics
7.06%
ObsEva SA stock logo
OBSV
ObsEva
17.52%
Cortex Pharmaceuticals Inc. stock logo
RSPI
Cortex Pharmaceuticals
N/A
Traws Pharma, Inc. stock logo
TRAW
Traws Pharma
7.95%

Insider Ownership

CompanyInsider Ownership
Indaptus Therapeutics, Inc. stock logo
INDP
Indaptus Therapeutics
20.80%
ObsEva SA stock logo
OBSV
ObsEva
14.40%
Cortex Pharmaceuticals Inc. stock logo
RSPI
Cortex Pharmaceuticals
50.03%
Traws Pharma, Inc. stock logo
TRAW
Traws Pharma
13.60%
CompanyEmployeesShares OutstandingFree FloatOptionable
Indaptus Therapeutics, Inc. stock logo
INDP
Indaptus Therapeutics
6570,000453,000Not Optionable
ObsEva SA stock logo
OBSV
ObsEva
5077.97 million66.74 millionNot Optionable
Cortex Pharmaceuticals Inc. stock logo
RSPI
Cortex Pharmaceuticals
2949.46 million474.45 millionNot Optionable
Traws Pharma, Inc. stock logo
TRAW
Traws Pharma
175.56 million4.81 millionOptionable

Recent News About These Companies

Traws Pharma announces chief financial officer transition
Traws Pharma reports FY24 EPS ($35.21)
Traws Pharma Reports Full Year 2024 Results and Business Highlights

New MarketBeat Followers Over Time

Media Sentiment Over Time

Indaptus Therapeutics stock logo

Indaptus Therapeutics NASDAQ:INDP

$10.22 -0.57 (-5.28%)
Closing price 07/3/2025 03:55 PM Eastern
Extended Trading
$10.11 -0.11 (-1.08%)
As of 07/3/2025 04:33 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Indaptus Therapeutics, Inc., a clinical biotechnology company, develops various anti-cancer and anti-viral immunotherapy products. Its lead clinical candidate is Decoy20 used to produce single agent activity and/or combination therapy-based durable responses of lymphoma, hepatocellular, colorectal, and pancreatic tumors, and chronic hepatitis B virus, and human immunodeficiency virus infection, which is in Phase 2 clinical trial. The company was formerly known as Intec Parent, Inc. and changed its name to Indaptus Therapeutics, Inc. in August 2021. Indaptus Therapeutics, Inc. is headquartered in New York, New York.

ObsEva stock logo

ObsEva NASDAQ:OBSV

ObsEva SA is a clinical-stage biopharmaceutical company, which engages in the research and development of therapeutic treatments for women's reproductive health and pregnancy. It offers biopharmaceutical drugs addressing conditions compromising pregnancy from conception to birth. The company was founded by Ernest Loumaye and André Chollet on November 14, 2012 and is headquartered in Geneva, Switzerland.

Cortex Pharmaceuticals stock logo

Cortex Pharmaceuticals OTCMKTS:RSPI

$0.0008 0.00 (-11.11%)
As of 07/3/2025 12:38 PM Eastern

RespireRx Pharmaceuticals Inc. engages in the discovery, development, and commercialization of pharmaceuticals for the treatment of neurological and psychiatric disorders. It has two drug platforms comprising ResolutionRx, a pharmaceutical cannabinoids platform, which includes dronabinol that acts upon the CB1 and CB2 endocannabinoid receptors for use in chemotherapy-induced nausea and vomiting, as well as for anorexia in patients with AIDS and obstructive sleep apnea; and EndeavourRx, a neuromodulators platform that comprises AMPAkines program, including proprietary compounds that are positive allosteric modulators (PAMs) of glutamate receptors to promote neuronal function, and GABAkines program, including proprietary compounds that are PAMs of GABAA receptors. The company's lead ampakine, CX1739, which has completed Phase II clinical studies for opioid-induced respiratory depression, as well as for central sleep apnea. It is also developing CX717, CX1739, and CX1942 that have clinical application in the treatment of CNS-driven neurobehavioral and cognitive disorders, spinal cord injury, neurological diseases, and various orphan indications. It has a research collaboration with University College London to the use of AMPAkines for the treatment of GRIA disorders. The company was formerly known as Cortex Pharmaceuticals, Inc. and changed its name to RespireRx Pharmaceuticals Inc. in December 2015. RespireRx Pharmaceuticals Inc. was incorporated in 1987 and is headquartered in Glen Rock, New Jersey.

Traws Pharma stock logo

Traws Pharma NASDAQ:TRAW

$1.43 -0.03 (-2.05%)
Closing price 07/3/2025 03:58 PM Eastern
Extended Trading
$1.48 +0.05 (+3.15%)
As of 07/3/2025 04:37 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Traws Pharma, Inc., a clinical stage biopharmaceutical company, focuses on developing small molecule oral product candidates for respiratory viral diseases and cancer. The company is developing investigational novel therapies for influenza and COVID19 that are designed to address treatment resistance, such as TRX01 (travatrelvir), a Mpro/3CL inhibitor in development for the treatment of COVID19; and TRX100 (viroxavir), an endonuclease inhibitor in development for the treatment of pandemic influenza. It is also developing narazaciclib, a multi-kinase CDK4/6 inhibitor, which is in Phase 1/2 clinical trials in patients with cancer, with or without co-administration of letrozole to define the recommended phase 2 dose for further development in endometrial cancer; and oral rigosertib, which is administered alone or in combination for investigation in various cancers. The company was formerly known as Onconova Therapeutics, Inc. and changed its name to Traws Pharma, Inc. in April 2024. Traws Pharma, Inc. was incorporated in 1998 and is headquartered in Newtown, Pennsylvania.